What Is the Treatment for Gastrointestinal Angiodysplasia?

Gastrointestinal angiodysplasia (ICD-10 K55.3 / ICD-11 DA97) is a vascular condition of the GI tract associated with bleeding that may be recurrent. First-line management is guided by measurable haematological targets and a preference for the least invasive effective intervention.

Treatment Goals

Management is assessed on cessation of active bleeding and prevention of rebleeding, alongside objective haematological stability — specifically, no further drop in haemoglobin beyond 1 g/dL or haematocrit beyond 5% following the intervention.

First-Line Treatment Approach

Evidence supports starting with less invasive options: a pharmacological strategy drawing on more than one drug class is prioritised before considering escalation. The full structured regimen specifies which agents apply and under what conditions.

Instant Access to Structured Evidence-Based Regimens

References

Less invasive treatments should be prioritized as initial options.
Pharmacological therapies involving octreotide, thalidomide, or female sex hormones have also been used.
Nevertheless, management is mainly assessed based on the cessation of bleeding, prevention of rebleeding, and improvement in a person's clinical status.
Stability of hemoglobin/hematocrit levels: no further drop beyond 1 g/dL for hemoglobin and 5% for hematocrit following the intervention.

DOI: 10.1002/14651858.CD014582.

View source ↗